Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 875 shares of Protagonist Therapeutics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $20.00, for a total transaction of $17,500.00. Following the completion of the transaction, the insider now owns 4,697 shares in the company, valued at approximately $93,940. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
David Y. Liu also recently made the following trade(s):
- On Monday, November 13th, David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $118,790.00.
Shares of Protagonist Therapeutics Inc (PTGX) traded up $0.08 on Wednesday, hitting $19.46. 139,716 shares of the company’s stock were exchanged, compared to its average volume of 102,872. The firm has a market cap of $397.55 and a price-to-earnings ratio of -7.00. Protagonist Therapeutics Inc has a 52 week low of $8.00 and a 52 week high of $21.68.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.40. The company had revenue of $8.78 million during the quarter. analysts predict that Protagonist Therapeutics Inc will post -3.66 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in PTGX. Senzar Asset Management LLC purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at $3,094,000. Northern Trust Corp raised its stake in shares of Protagonist Therapeutics by 24.0% in the 2nd quarter. Northern Trust Corp now owns 98,825 shares of the company’s stock valued at $1,118,000 after acquiring an additional 19,159 shares during the period. First Manhattan Co. purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter valued at $293,000. FMR LLC raised its stake in shares of Protagonist Therapeutics by 0.4% in the 2nd quarter. FMR LLC now owns 2,528,462 shares of the company’s stock valued at $28,597,000 after acquiring an additional 10,264 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Protagonist Therapeutics by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock valued at $3,680,000 after acquiring an additional 11,881 shares during the period. Institutional investors own 39.68% of the company’s stock.
A number of equities analysts have weighed in on PTGX shares. Zacks Investment Research lowered shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 18th. BMO Capital Markets decreased their price target on shares of Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 19th. Finally, BidaskClub lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $32.67.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Protagonist Therapeutics Inc (PTGX) Insider Sells 875 Shares of Stock” was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.truebluetribune.com/2018/01/17/insider-selling-protagonist-therapeutics-inc-ptgx-insider-sells-875-shares-of-stock.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.